MoonLake Immunotherapeutics

MLTX

Market cap $3.34B

Overview Fund Activity

52.62 USD

-1.68

3.09%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

52.62

0.00

0%

1 day

-3.09%

5 days

-11.56%

1 month

-4.05%

3 months

19.54%

6 months

33.86%

Year to date

-1.77%

1 year

3.1%

5 years

401.62%

10 years

401.62%

About: MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Employees: 100

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

19% more capital invested

Capital invested by funds: $2.34B [Q1] → $2.77B (+$434M) [Q2]

5% more call options, than puts

Call options by funds: $39.6M | Put options by funds: $37.7M

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

2.06% less ownership

Funds ownership: 94.65% [Q1] → 92.59% (-2.06%) [Q2]

4% less funds holding

Funds holding: 136 [Q1] → 130 (-6) [Q2]

15% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 27

27% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 51

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$82

56% upside

Avg. target

$82

56% upside

High target

$82

56% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Goldman Sachs

Richard Law

$82

Buy

Maintained

6 Aug 2025

See Analyst Rankings

Financial journalist opinion

2 Logical Mid-Cap Biotech Buyout Targets

There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on their own, but would make logical buyout candidates: Abivax Société Anonyme and MoonLake Immunotherapeutics. Both have late-stage assets targeting large markets, and both companies should file for their first FDA approvals in 2026.

2 Logical Mid-Cap Biotech Buyout Targets

The Motley Fool

2 Small-Cap Biotech Stocks Well Positioned for a Breakout

For decades, savvy investors have been finding stocks that can produce dramatic gains in relatively short timeframes by sifting through the biotechnology universe. In this wonky industry, positive clinical trial results can cause small-cap stocks to double in value in a single trading session.

2 Small-Cap Biotech Stocks Well Positioned for a Breakout

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

ZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the second quarter of 2025.

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

Zacks Investment Research

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

MoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is projected to reach $24.2 billion by the end of 2031. Merck's $3 billion non-binding acquisition offer highlights significant buyout potential of company and validates its late-stage pipeline value.

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

Investors Business Daily

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion."

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Zacks Investment Research

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody ® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA) Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trial Presented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab in an indication with currently no approved therapeutics in the US and Europe, and further derisking the overall development of sonelokimab Ended the first quarter with $480.1 million in cash, cash equivalents and short-term marketable debt securities and announced closing of a debt facility, providing up to $500 million in non-dilutive funds and extending expected cash runway into 2028 ZUG, Switzerland, May 12, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the first quarter of 2025. Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics, said: “We continue executing across our portfolio of indications with quality, speed and efficiency.

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtual Capital Markets Day for investors and analysts on Tuesday, April 29, 2025. The event will highlight recent financial and clinical milestones and provide future strategic updates.

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

See News Rankings

Charts implemented using Lightweight Charts™